登录  |  注册  |  设为首页  |  加入收藏  |  联系我们  |  繁体版

您当前的位置: 首页>>English >>Research on China Monoclonal Antibody (McAB) Industry, 2014

Research on China Monoclonal Antibody (McAB) Industry, 2014

慧典市场研究报告网(www.hdcmr.com)

Research on China Monoclonal Antibody (McAB) Industry, 2014

  • 【报告编号】: 657305
  • 【最新修订】: 2014年07月01日
  • 【关 键 字】: Monoclonal Antibody (McAB)
  • 【报告页数】: 60
  • 【报告格式】: 电子版或纸介版
  • 【交付方式】: Email发送或EMS快递
  • 【价    格】: 纸介版:$2200    电子版:$2000
  • 【订购热线】: 010-51263229    010-51265563
报告导读:

报告目录

查看全部>>

Research on China Monoclonal Antibody (McAB) Industry, 2014

1. Overview of Monoclonal Antibody 
1.1 Definition and Characteristics 
1.2 Preparation Process of Monoclonal Antibody 
1.3 Classification 
1.4 Mechanism of Action 
1.5 Key Technology 

2. Operation Environment of China’s Monoclonal Antibody Industry
2.1 Analysis of Economic Environment 
2.2 Policy Analysis 
2.2.1 Monoclonal Antibody Industry Ranks as a Strategic Emerging Industry
2.2.2 NCCN Guidance Supports Monoclonal Antibody Agents; McAB Agents are Included into Local Health Insurance

3. Current Situation and Tendencies of Worldwide Monoclonal Antibody Industry
3.1 Development History Overview of International Monoclonal Antibody Market 
3.2 Monoclonal Antibody Agents Listing in Market  
3.3 Global Key Enterprises Devoting to Developing Monoclonal Antibody Agents 
3.4 Powerful Growth Momentum of Global Antibody Market 
3.5 Development Tendency and Outlook of Global Monoclonal Antibody Agents 
3.5.1 Develop Monoclonal Antibody Aiming at New Target Spots 
3.5.2 Diversified Research and Development on Monoclonal Antibody 
3.5.3 Antibody-Drug-Conjugates (ADCs) as a New Research Hotspot and Development Direction 
3.5.4 First Monoclonal Antibody Biological Analogue Approved in European and American Market

4. Operation Situation of China’s Monoclonal Antibody Industry
4.1 Small Market Size 
4.2 Listing Situation of Monoclonal Antibody Agents 
4.3 Comparison of Research Progress between China and Foreign Countries 
4.3.1 China’s Research Progress on Monoclonal Antibody
4.3.2 Differences of New R& D Ability and Industrialization between China and Foreign Countries 
4.4 The First Climax of Monoclonal Antibody: 2017 to 2020

5. China’s Key Monoclonal Antibody Agent Enterprises
5.1 Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ)
5.1.1 Company Profile 
5.1.2 Business Condition 
5.1.3 The Generic Drug of Trastuzumab – Sai Pu Ting Approved for Clinical Use 
5.2 Biotech Pharmaceuticals Co., Ltd. 
5.2.1 Company Profile 
5.2.2 Business Condition 
5.2.3 Production Process 
5.3 Chengdu Huasun Biotechnology Co., Ltd. 
5.3.1 Company Profile 
5.3.2 Representative Products 
5.3.3 Business Condition 
5.4 Zhejiang HISUN Pharmaceutical Co., Ltd. 
5.4.1 Company Profile 
5.4.2 Business Condition 
5.4.3 Progress of R & D
5.5 Shanghai Bio Pharmaceutical Co., Ltd. 
5.5.1 Company Profile 
5.5.2 Business Condition 
5.5.3 Progress of R & D

6. Huge Growth Potential and Development Opportunities of China Monoclonal Antibody Market in the Future 
6.1 Enormous China’s Market Space and Potential Medical Demand not Get Satisfied 
6.2 Late-Mover Advantage and Unique Opportunity of China Monoclonal Antibody Market 

报告描述

查看全部>>
Research on China Monoclonal Antibody (McAB) Industry, 2014 mainly carries on in-depth analysis on policy environment, global market, Chinese market, as well as the latest developments of domestic key enterprises related to China’s monoclonal antibody industry.

Several Chinese large-scale pharmaceutical enterprises devoted themselves to research and development of monoclonal antibody agents, which have achieved results in 2013. Hengrui Medicine Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and Qilu Pharm have applied for clinical research of monoclonal antibody agents. And Walvax Biotechnology Co., Ltd even made a huge investment in purchasing Genor Biopharma Co., Ltd, attempting to establish a large biological strategy. Although large-scale pharmaceutical enterprises entered monoclonal antibody field on a large scale, the overall innovation is still insufficient, and the market is represented by monoclonal antibody agents and biological analogue that have submitted applications, few imitated drugs, and innovative medicines are rare and precious things, mainly on account of high risks and long-time cycle.

Due to late state, China’s strength on research and development will be still vulnerable within future three to five years, so it has to open the market preliminarily by depending on generic drugs. In 2013, the market size was CNY 3.8 billion around, up 30% year-on-year; product categories and sales volume were far less than that of European and American countries.

According to statistical data of Shanghai Pharmaceutical Profession Association (SPPA), China will see four to six monoclonal antibody agents by 2016, such as Trastuzumab and Rituximab. And it is expected by 2020, six to ten monoclonal antibody agents will be listed in market, and some of which are independently researched drugs. Huidian Research believes that China’s monoclonal antibody market will embrace its first climax from 2017 to 2020.

相关研究报告

报告搜索

  • 研究报告
  • 免费报告

购买流程

1.选择报告

① 按行业浏览 点击研究首页左边的行业分类 ② 按名称查询 输入关键字进行站内搜索

2.订购方式

① 电话购买:010-51263229 010-51265563 ② 在线订购 点击您需求的报告在线订购系统,在您注册填写正确的联系资料后,我们的服务人员会在24小时以内与您取得联系。 ③ 邮件定购 发送邮件到:

3.购买流程

  • (1)确定购买意向电话或网络确定购买细节
  • (2)签订服务合同签订研究报告购买合同
  • (3)签订服务合同支付报告购买款项
  • (4)购买成功支付报告并售后服务一年

4.汇款信息

开户名:北京市北福源信息咨询有限公司 帐 号:35090188000014650 开户行:光大银行亚运村支行

手机扫描二维码区域

版权所有:慧典市场研究报告网

电话:(86)010-51265563 010-51263229 传真:010-84985706   客服邮件:

京ICP备05012231号-1